- Trials with a EudraCT protocol (56)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
56 result(s) found for: Transfer factor.
Displaying page 1 of 3.
EudraCT Number: 2015-005576-22 | Sponsor Protocol Number: 201501 | Start Date*: 2018-05-22 | |||||||||||
Sponsor Name:BAXALTA INNOVATIONS GMBH | |||||||||||||
Full Title: A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVII... | |||||||||||||
Medical condition: Hemophilia A is a rare congenital disease characterized by reduced or absent levels of the coagulation FVIII. It occurs in approximately 1 in 5,000 live male births. Mutations of the FVIII gene res... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004024-11 | Sponsor Protocol Number: SHP648-101 | Start Date*: 2020-05-04 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects | |||||||||||||
Medical condition: Hemophilia B is a X-linked recessive bleeding disorder caused by mutations in the gene encoding clotting factor IX (FIX) that result in disruption of the normal clotting pathway. Hemophilia B affec... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003484-56 | Sponsor Protocol Number: BOLDOS-18 | Start Date*: 2019-12-26 | |||||||||||
Sponsor Name:Miguel Caballero Campo | |||||||||||||
Full Title: Efficacy of corifolitropin alfa in double ovarian stimulation compared with two conventional ovarian stimulation cycles for embryo accmulation in low responder patients. Multicenter randomized cont... | |||||||||||||
Medical condition: Infertility in patients requiring in vitro fertilization treatment with poor ovarian response profile, defined by Bologna Criteria. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005711-17 | Sponsor Protocol Number: AGT4HB | Start Date*: 2009-09-25 | ||||||||||||||||
Sponsor Name:St. Jude Children’s Research Hospital | ||||||||||||||||||
Full Title: AN OPEN LABEL DOSE-ESCALATION STUDY OF A SELF COMPLEMENTARY ADENO-ASSOCIATED VIRAL VECTOR (scAAV2/8-LP1-hFIXco) FOR GENE TRANSFER IN SUBJECTS WITH HEMOPHILIA B | ||||||||||||||||||
Medical condition: Gene therapy for Haemophilia B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: GB (Temporarily Halted) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000806-39 | Sponsor Protocol Number: BAY2599023/19429 | Start Date*: 2019-02-25 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with sever... | |||||||||||||
Medical condition: Hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001094-33 | Sponsor Protocol Number: BO39182 | Start Date*: 2016-08-08 | ||||||||||||||||
Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd. | ||||||||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS (Q4W) IN PATIENTS WITH HEMOPHILIA A | ||||||||||||||||||
Medical condition: Hemophilia A | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Temporarily Halted) PL (Completed) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001669-17 | Sponsor Protocol Number: 000004 | Start Date*: 2013-09-17 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stim... | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DK (Completed) PL (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003788-36 | Sponsor Protocol Number: NN7088-4410 | Start Date*: 2018-03-12 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: LT (Completed) GB (GB - no longer in EU/EEA) PT (Completed) GR (Completed) NO (Completed) DK (Completed) HU (Completed) FR (Completed) NL (Completed) DE (Completed) ES (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003213-34 | Sponsor Protocol Number: 270-205 | Start Date*: 2020-09-25 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Active or Prior Inhibitors | |||||||||||||
Medical condition: Hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003215-19 | Sponsor Protocol Number: 270-301 | Start Date*: 2017-11-25 |
Sponsor Name:BioMarin Pharmaceutical Inc. | ||
Full Title: A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Res... | ||
Medical condition: Haemophilia A | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) FR (Completed) BE (Completed) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005524-11 | Sponsor Protocol Number: FNO-IMUNOR-2020 | Start Date*: 2020-12-21 |
Sponsor Name:Fakultní nemocnice Ostrava | ||
Full Title: Pilot, monocentre, phase-IV clnical trial assessing the clinical effect of per oral immunomodulation treatment using the IMUNOR® preparation in the prevention of COVID-19 disease | ||
Medical condition: COVID-19 prevention | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002443-38 | Sponsor Protocol Number: C0371006 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: Phase 3 open-label study to evaluate efficacy, safety, and tolerability of FIX gene transfer with fidanacogene elaparvovec (PF-06838435) in pediatric male participants <18 years of age with moderat... | |||||||||||||
Medical condition: moderately severe to severe hemophilia B (FIX:C≤2%) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003573-34 | Sponsor Protocol Number: 270-302 | Start Date*: 2018-02-23 |
Sponsor Name:BioMarin Pharmaceutical Inc. | ||
Full Title: A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemoph... | ||
Medical condition: Haemophilia A | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Completed) BE (Completed) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003086-33 | Sponsor Protocol Number: C0371002 | Start Date*: 2020-01-28 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe he... | |||||||||||||
Medical condition: severe to moderately severe hemophilia B <=2% | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003073-28 | Sponsor Protocol Number: 8HA02PED | Start Date*: 2012-05-31 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Ltd | ||||||||||||||||||
Full Title: An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episod... | ||||||||||||||||||
Medical condition: Severe Hemophilia A | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: GB (Completed) IE (Completed) NL (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002783-40 | Sponsor Protocol Number: 000304 | Start Date*: 2019-07-04 | |||||||||||||||||||||||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||||||||||||||||||||||
Full Title: A randomised, controlled, open label, parallel group, multicentre trial comparing the efficacy and safety of individualised FE 999049 (follitropin delta) dosing, using a long GnRH agonist protocol ... | |||||||||||||||||||||||||||||||||
Medical condition: Infertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||
Trial protocol: AT (Completed) DK (Completed) NO (Completed) NL (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000753-80 | Sponsor Protocol Number: 000298 | Start Date*: 2022-08-04 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, assessor-blind, active-controlled, parallel-group, dose-finding trial to investigate the efficacy and safety of FE 999302 for triggering of final follicular maturation in women underg... | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) CZ (Prematurely Ended) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000662-29 | Sponsor Protocol Number: 270-203 | Start Date*: 2018-02-01 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels ≤ 1... | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006775-67 | Sponsor Protocol Number: FE 999906 CS08 | Start Date*: 2009-04-29 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, open-label, assessor-blind, parallel groups, multicentre trial compating the efficacy of MENOPUR versus recombinant FSH in controlled ovarian stimulation following a GnRH antagonist p... | |||||||||||||
Medical condition: Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (ART) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) ES (Completed) CZ (Completed) PL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001486-67 | Sponsor Protocol Number: 101HEMB01 | Start Date*: 2016-07-21 | |||||||||||
Sponsor Name:Dimension Therapeutics, Inc. | |||||||||||||
Full Title: A Phase I/II Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B | |||||||||||||
Medical condition: Moderate/severe to severe hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
